**Decipher Labs Limited** (formerly **Combat Drugs Limited**) is a Hyderabad-based enterprise incorporated in **1989**. The company has evolved from a traditional pharmaceutical manufacturer into a hybrid entity that integrates legacy medicinal production with high-growth technology consultancy services. Currently, the group is navigating a strategic "recalibration" phase, balancing international expansion in the **United States** with significant regulatory challenges in its home market of **India**. --- ### **Dual-Core Business Model & Revenue Streams** The Group operates through two distinct reporting segments, leveraging an asset-light model that utilizes third-party facilities for sourcing to maintain operational flexibility. * **Consultancy Services:** This is the primary revenue driver, focused on technology and software-related consultancy. It is operated largely through international subsidiaries and services global clients, particularly in the healthcare provider space. * **Pharmaceutical Manufacturing & Trading:** The legacy business involving the production and distribution of medicinal products. This segment is currently facing contraction and high concentration risks. #### **Segmented Revenue Performance (FY2024 vs. FY2025)** | Segment | Revenue (Mar 2025) | Revenue (Mar 2024) | | :--- | :--- | :--- | | **Consultancy Services** | **₹2,192.65 Lakhs** | **₹3,260.52 Lakhs** | | **Pharma Manufacturing/Trading** | **₹68.60 Lakhs** | **₹327.33 Lakhs** | | **Total Revenue from Operations** | **₹2,261.25 Lakhs** | **₹3,587.85 Lakhs** | --- ### **Strategic Pivot: Geographic Consolidation & Niche Focus** In **August 2025**, the Board of Directors initiated a major strategic restructuring to mitigate geopolitical risks and optimize EBITDA margins. * **The "US-First" Strategy:** Operations are being consolidated strictly within the **United States** via the **100% Wholly Owned Subsidiary, Decipher Software Solutions LLC**. This unit is the vehicle for scaling IT services and acquiring high-tech barrier products. * **Middle East Exit:** The Board approved the closure of the **Decipher Soft Middle East W.L.L. (Bahrain)** office due to market contraction and regional volatility. Management expects this to have a **negligible financial impact** as the region's contribution was minimal. * **Product Acquisition Strategy:** The company is shifting away from high-volume generics toward **low-competition niche products** and **complex offerings** with high entry barriers to protect margins against pricing pressures. * **Operational Trimming:** The company is transitioning from a period of "experimentation" to a lean model focused on narrowing business fields to maximize profitability. --- ### **Financial Health & Historical Trends** The company has experienced significant volatility in its consolidated top-line and bottom-line performance over the last three fiscal cycles. #### **Consolidated vs. Standalone Performance** | Fiscal Year | Entity | Total Income | Net Profit / (Loss) | | :--- | :--- | :--- | :--- | | **FY 2022-23** | Consolidated | **₹52.94 Crore** | **(₹95.66 Lakhs)** | | **FY 2022-23** | Standalone | **₹83.82 Lakhs** | **(₹2.62 Crore)** | | **FY 2021-22** | Consolidated | **₹73.00 Crore** | **₹11.94 Crore** | | **FY 2021-22** | Standalone | **₹1.03 Crore** | **₹36.04 Lakhs** | | **FY 2020-21** | Standalone | **₹1.12 Crore** | **₹9.61 Lakhs** | **Key Financial Observations:** * **Revenue Contraction:** Consolidated income dropped by approximately **27.5%** between **FY22** and **FY23**. * **Efficiency Metrics:** The **Debtors Turnover** ratio fell from **4.72** to **1.73** (**-63%**) in the most recent cycle due to an increase in outstanding debtors. * **Inventory Management:** The **Inventory Turnover** ratio reached **0** as the company held **no closing stock** at year-end, reflecting its shift toward an asset-light/trading model. --- ### **Corporate Governance & Human Capital** Decipher Labs maintains a lean corporate structure with a high degree of dematerialized shareholding (**93.77%**). * **Board Composition:** 5 Directors, including **3 Independent Directors** and **2 Women Directors**. * **Key Leadership:** * **Janaki Ram Ajjarapu:** Non-Executive Director and major shareholder (**16.43%** equity). * **Sushant Mohan Lal:** Executive Whole Time Director (**2.14%** equity). * **Dalavath Amarsingh:** Appointed as **Whole-time Director** (effective Feb 2026) to lead future growth initiatives. * **Workforce Metrics:** The company operates with **1 permanent employee** on the rolls. The **Median Remuneration of Employees (MRE)** saw a sharp increase of **94.39%** to **₹2,70,000** in **FY 2024-25**. * **Director Alignment:** In **FY 2022-23**, key directors waived portions of their remuneration to support the company’s financial stability during a loss-making period. --- ### **Critical Risk Factors & Regulatory Constraints** Investors should note significant headwinds that may impact the company's ability to execute its growth strategy. #### **1. SEBI Restrictive Orders (July 2025)** The company is currently under a **3-year debarment** from the securities market following a SEBI order regarding **Insider Trading violations** (Regulations 3 and 4). * **Penalties:** **Janakiram Ajjarapu** was fined **₹60 Lakhs** with a disgorgement of **₹7.91 Crore**; **Sushant Mohan Lal** was fined **₹35 Lakhs** with a disgorgement of **₹2.31 Crore**. * **Impact:** All aggressive **Joint Ventures (JVs)** and **Takeovers** in the USA and India have been **officially paused** as of **August 14, 2025**. The company is currently appealing this order in the **Securities Appellate Tribunal (SAT)**. #### **2. Operational Vulnerabilities** * **Customer Concentration:** **72.87%** of total revenue is derived from a **single customer**, creating a high-stakes dependency. * **Compliance Gaps:** The company’s accounting software (**Tally Prime 2.0**) currently lacks the mandatory **audit trail (edit log)** feature required under the **Companies (Accounts) Rules, 2014**. * **Market Pressures:** The pharmaceutical segment faces margin erosion due to **anti-dumping policies**, generic pricing competition, and supply chain shifts away from **China**. #### **3. Financial Risk Management** * **Currency Risk:** The company is highly sensitive to **USD/INR** fluctuations. While it uses **forward covers** for net exposure, it does not engage in speculative hedging. * **Liquidity Covenants:** Interest-bearing loans are subject to strict **financial covenants**; any breach allows lenders to demand immediate repayment.